Quality control is of utmost importance when considering treatment with MSCs for COVID-19; in addition to investigating the infectivity potential of MSCs, attention should also be given to concerns about the variability of TF/CD142 expression among cells lots, which may trigger blood clotting and thromboembolism in this hypercoagulable pathology [48]. The gene discussed is F3; the disease is COVID-19.